Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Yale opens center to study cannabis and cannabinoids

By Brian Buntz | January 31, 2023

Cannabidiol

[CBD molecule courtesy of PubChem]

Yale School of Medicine has established a research center, the Yale Center for the Science of Cannabis and Cannabinoids, to investigate how cannabis and cannabinoids affect neurodevelopment and mental health. Led by Dr. Deepak Cyril D’Souza, an expert in cannabinoid pharmacology, the center will use a multidisciplinary approach to study the acute and chronic effects of these substances. 

Yale psychiatry chair Dr. John H. Krystal, and the university’s dean of medicine, Dr. Nancy J. Brown, announced the establishment of the new cannabinoids center on January 30, 2023. 

The two said the center’s opening was timely given the rapid commercialization of cannabis in the U.S. In addition to internal funding, the new center will intend to secure a P50-type center grant for further research.

Booming cannabinoids interest but relatively limited research

Interest in cannabinoids has increased in recent years, although the fact that cannabis remains a Schedule I substance has constrained research. 

Cannabidiol (CBD), a non-psychoactive compound in the cannabis plant, has emerged as a popular supplement. The compound shows promise for various conditions, including pain, anxiety, depression, inflammation, seizures and neurodegenerative diseases such as Parkinson’s and Alzheimer’s. CBD may also have potential as an anti-inflammatory, neuroprotective and antipsychotic agent.

A study in early 2022 found that cannabinoid acids may protect against COVID-19.  

The quality of evidence for most conditions, however, remains generally low. 

FDA approved Epidiolex (cannabidiol) to treat certain severe seizure disorders in 2018. 

The UK-based company GW Pharmaceuticals originally developed Epidyolex. Jazz Pharmaceuticals acquired GW for approximately $7.2 billion in 2021.

FDA looking at new ways to regulate CBD

FDA, however, has noted that it believes a new regulatory pathway for CBD is required to regulate the use of CBD as a food additive and dietary supplement. 

The marketing of CBD-based products continues to be illegal under FDA regulation, but such products are widely available in many U.S. states. 

The agency notes that studies indicate that the compound may harm the liver and possibly damage the male reproductive system. 

FDA also says CBD is a potential threat to animals and that people may unknowingly ingest CBD through products such as meat, milk and eggs from animals fed CBD.  


Filed Under: Psychiatric/psychotropic drugs
Tagged With: cannabidiol, CBD
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Why Cybin’s CEO sees RFK Jr. and J&J’s ketamine clinics as keys to clinical psilocybin’s mainstream moment
Muse Clinic: Innovating with Psychedelics and Neurotechnology
Can LSD break the 20-year drought in anxiety treatment?
MAPS
FDA rejection of MDMA and journal retractions jolt psychedelic therapy research
MDMA
Experts endorse MDMA-assisted therapy for PTSD amid FDA adcomm setback
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE